Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in Patients with Advanced and Recurrent Cervical Cancer Regardless of Bevacizumab Use By Ogkologos - November 25, 2024 781 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the subgroup analysis of the KEYNOTE-826 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... June 30, 2022 Sheriff’s Sergeant Is Now Fighting Stage III Breast Cancer After Missing... July 16, 2021 Pioneer in Autism Diagnosis And Treatment Dies At 97 September 21, 2021 New Safety Signal for Use of Ibrutinib in Combination with Rituximab... September 15, 2021 Load more HOT NEWS Could A Form of Cell Death Enhance Cancer Immunotherapy? FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,... FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate...
